Cervical and Vaginal Microbiomes in Early Miscarriages and Ongoing Pregnancy with and without Dydrogesterone Usage

Int J Mol Sci. 2023 Sep 8;24(18):13836. doi: 10.3390/ijms241813836.

Abstract

Emerging evidence suggests that the reproductive tract microbiota is a key modulator of local inflammatory and immune pathways throughout pregnancy and may subsequently impact pregnancy outcomes. In this study, our objective was to analyze the cervical and vaginal microbiomes during early pregnancy among three groups: women with healthy ongoing pregnancies, women undergoing dydrogesterone treatment, and those who experienced miscarriages. The experiment involved 51 women at 8-11 weeks of gestation. The microbiome was examined using 16S rRNA sequencing on the Ion Torrent PGM platform. Across all groups, Lactobacillus iners was predominant, suggesting that the vaginal community type CST III is common among the majority of participants. Notably, our data highlighted the significant roles of Gardnerella vaginalis and Mycoplasma girerdii in the pathogenesis of early miscarriage. Conversely, L. iners and Bifidobacterium longum have a protective effect in early pregnancy. Moreover, dydrogesterone intake appeared to influence notable differences between the cervical and vaginal microbiomes. Overall, our study enhanced our understanding of the cervical and vaginal microbiome composition in the eastern European population during early pregnancy.

Keywords: 16S rRNA; Bifidobacterium; Gardnerella vaginalis; Lactobacillus iners; Mycoplasma; NGS; cervical microbiome; dydrogesterone; early pregnancy; miscarriage; vaginal microbiome.

MeSH terms

  • Abortion, Spontaneous*
  • Dydrogesterone / therapeutic use
  • Female
  • Humans
  • Microbiota* / genetics
  • Pregnancy
  • RNA, Ribosomal, 16S / genetics
  • Vagina

Substances

  • Dydrogesterone
  • RNA, Ribosomal, 16S